IAN E KROP
Affiliation: Massachusetts General Hospital
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAI E Krop
Department of Medical Oncology, Dana Farber Cancer Institute, Boston
Ann Oncol 26:113-9. 2015....
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialIAN E KROP
Dana Farber Cancer Institute, Harvard University School of Medicine, Boston, MA, USA Electronic address
Lancet Oncol 15:689-99. 2014..We aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastuzumab, with treatment of physician's choice in this population of patients...
- Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancerL M Flores
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Br J Cancer 102:1495-502. 2010..Circulating tumour cells (CTCs) offer a non-invasive approach to obtain and characterise metastatic tumour cells, but their usefulness has been limited by low CTC yields from conventional isolation methods...
- Chemokine signaling in gliomas: prognostic factor, therapeutic target or both?IAN E KROP
Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Biol Ther 5:1039-41. 2006
- A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabineIAN E KROP
Dana Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215, USA
J Clin Oncol 30:3234-41. 2012....
- Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstructionKari Joanne Kansal
Brigham and Women s Hopspital, Boston, MA, USA
Breast Cancer Res Treat 141:255-9. 2013..As larger data sets become available with the use of neoadjuvant bevacizumab with mastectomy, further refinement may be necessary. ..
- Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerIAN E KROP
Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
J Clin Oncol 28:2698-704. 2010..This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-positive breast cancer...
- Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonistsXiuwei H Yang
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute and Harvard Medical School, University of Massachusetts, Boston, Massachusetts, USA
Cancer Res 70:2256-63. 2010..These new insights should be useful when devising strategies for overcoming drug resistance in ErbB2+ cancers...
- A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastasesRachel A Freedman
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
Clin Breast Cancer 11:376-83. 2011..We observed modest activity with a central nervous system objective response rate of 13.3%; however, median PFS was disappointing. Further studies should focus on other agents to treat this challenging clinical problem...
- Prospective clinical experience with research biopsies in breast cancer patientsInes Vaz-Luis
Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
Breast Cancer Res Treat 142:203-9. 2013..This supports continued efforts to study tissue samples at multiple points in a patient's disease course...
- Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort studyInes Vaz-Luis
Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
Clin Breast Cancer 13:254-63. 2013..In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration...
- Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancerIAN E KROP
Breast Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
Breast Cancer Res 18:34. 2016..This phase 1b/2a study evaluated the safety/tolerability of T-DM1 + paclitaxel ± pertuzumab in HER2-positive advanced breast cancer...
- Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA
Invest New Drugs 33:1108-14. 2015..We conducted a phase 2 study of tivantinib monotherapy in patients with metastatic triple-negative breast cancer...
- A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancerSara M Tolaney
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
Cancer Med 3:293-9. 2014..Preoperative capecitabine is a well-tolerated regimen, but appears not lead to pCR when used as monotherapy in HR+ breast cancer...
- Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 InhibitorsShom Goel
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA Electronic address
Cancer Cell 29:255-69. 2016..In vivo, CDK4/6 inhibitors sensitize patient-derived xenograft tumors to HER2-targeted therapies and delay tumor recurrence in a transgenic model of HER2-positive breast cancer. ..
- Prevalence of germline TP53 mutations in HER2+ breast cancer patientsMichelle G Rath
Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
Breast Cancer Res Treat 139:193-8. 2013..Given the potential clinical impact, consideration of germline TP53 testing should be given to young women with HER2+ breast cancer, especially if family cancer history is notable...
- Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancersMarta Guix
Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
J Clin Oncol 26:897-906. 2008....
- Advances in targeting SRC in the treatment of breast cancer and other solid malignanciesErica L Mayer
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Clin Cancer Res 16:3526-32. 2010..Future trials will continue to explore the contribution of Src inhibition with both chemotherapy and targeted agents...
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey
Lisa A Carey, David W Ollila, Carey K Anders, Katherine A Hoadley, Michael Iglesia, and Charles M Perou, University of North Carolina Chapel Hill, Chapel Hill Constance T Cirrincione and Brandelyn N Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC Donald A Berry, Alliance Statistics and Data Center, MD Anderson, Houston, TX William T Barry, Alliance Statistics and Data Center, Dana Farber Cancer Institute Ian E Krop and Eric P Winer, Dana Farber Cancer Institute, Boston, MA Lyndsay N Harris, University Hospitals of Cleveland, Cleveland, OH Norah Lynn Henry, University of Michigan, Ann Arbor, MI Douglas J Weckstein, New Hampshire Hematology Oncology, Hooksett, NH Baljit Singh, New York University Clifford A Hudis, Memorial Sloan Kettering Cancer Center, New York, NY and Maggie Chon U Cheang, Clinical Trials and Statistics Unit, Institute of Cancer Research, Belmont, United Kingdom
J Clin Oncol 34:542-9. 2016..CALGB 40601 examined the impact of dual HER2 blockade consisting of trastuzumab and lapatinib added to paclitaxel, considering tumor and microenvironment molecular features...
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patientsSara M Tolaney
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02114
Proc Natl Acad Sci U S A 112:14325-30. 2015..This study implicates pretreatment MVD as a potential predictive biomarker of response to bevacizumab in BC and suggests that new therapies are needed to normalize vessels without pruning. ..
- Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancerIAN E KROP
Ian E Krop, Dana Farber Cancer Institute, Boston, MA Thomas M Suter, Bern University Hospital, Bern, Switzerland Chau T Dang, Memorial Sloan Kettering Cancer Center, New York Marc L Citron, Hofstra North Shore Long Island Jewish School of Medicine, New Hyde Park, NY Luc Dirix, Sint Augustinus Hospital, Antwerp, Belgium Gilles Romieu, Institut du Cancer de Montpellier Val d Aurelle, Montpellier Mario Campone, institut de cancérologie de l Ouest René Gauducheau, Nantes Saint Herblain, France Claudio Zamagni, Policlinico Sant Orsola Malpighi Hospital, Bologna Luca Gianni, San Raffaele Hospital, Milan, Italy and Na Xu and Melanie Smitt, Genentech, South San Francisco, CA
J Clin Oncol 33:1136-42. 2015....
- Mechanisms of trastuzumab resistance in breast cancerSara M Tolaney
Dana Farber Cancer Institute, Boston, MA 02115, USA
Anticancer Agents Med Chem 9:348-55. 2009..In this review, we discuss the mechanisms of antitumor activity of trastuzumab, potential mechanisms contributing to its resistance, and novel therapeutic agents that may provide a means to overcome trastuzumab resistance...